Current management strategies for systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 32, Issue SUPPL.81, 2014, Pages

  Nihtyanova, Svetlana I ^a   Ong, Voon H ^a   Denton, Christopher P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Systemic sclerosis; Treatment

Indexed keywords

HUMANS; IMMUNOSUPPRESSIVE AGENTS; SCLERODERMA, SYSTEMIC; STEROIDS;

EID: 84898799747     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. FRANSEN J, JOHNSON SR, Van Den HOOGEN F et al.: Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise with the ACR/EULAR working committee for classification criteria in systemic sclerosis. Arthritis Care Res 2012; 64: 351-7.
2. JOHNSON SR, FRANSEN J, KHANNA D et al.: Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 2012; 64: 358-67.
3. Van den HOOGEN F, KHANNA D, FRANSEN J et al.:2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
4. GIORDANO M, VALENTINI G, MIGLIARESI S, PICILLO U, VATTI M: Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13: 911-6.
5. MARICQ HR, VALTER I: A working classification of scleroderma spectrum disorders: A proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004; 22: S5-13.
6. LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
7. CLEMENTS PJ, HURWITZ EL, WONG WKEE et al.: Skin thickness score as a predictor and correlate of outcome in systemic sclerosis high-dose versus low-dose penicillamine trial. 2000; 43: 2445-54.
8. STEEN VD, MEDSGER TA: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828-35.
9. SHAND L, LUNT M, NIHTYANOVA S et al.: Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422-31.
10. COTTRELL TR, WISE RA, WIGLEY FM, BOIN F: The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 2013. [Epub ahead of print]
11. HANITSCH LG, BURMESTER G, WITT C et al.: Skin sclerosis is only of limited value to identify SSc patients with severe manifestations - an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register 2009; 70-3.
12. PERERA A, FERTIG N, LUCAS M et al.: Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-6.
13. HU PQ, FERTIG N, MEDSGER TA, WRIGHT TM: Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48: 1363-73.
14. KUWANA M, KABURAKI J, MIMORI T, KAWAKAMI Y, TOJO T: Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-84.
15. NIHTYANOVA SI, PARKER JC, BLACK CM, BUNN CC, DENTON CP: A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1218-21.
16. HESSELSTRAND R: The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003; 42: 534-40.
17. WALKER U, TYNDALL A, CZIRJÁK L et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
18. KUWANA M, KABURAKI J, OKANO Y, TOJO T, HOMMA M: Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.
19. HESSELSTRAND R, SCHEJA A, SHEN GQ, WIIK A, AKESSON A: The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-40.
20. HAMAGUCHI Y, HASEGAWA M, FUJIMOTO M et al.: The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008; 158: 487-95.
21. PENN H, HOWIE AJ, KINGDON EJ et al.: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-94.
22. BUNN CC, DENTON CP, SHI-WEN X, KNIGHT C, BLACK CM: Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998; 37: 15-20.
23. BARDONI A, ROSSI P, SALVINI R, BOBBIO-PALLAVICINI F, CAPORALI R, MONTECUCCO C: Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003; 21: 301-6.
24. CHANG M, WANG RJ, YANGCO DT, SHARP GC, KOMATIREDDY GR, HOFFMAN RW: Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1998; 89: 71-8.
25. KUWANA M, OKANO Y, PANDEY JP, SILVER RM, FERTIG N, MEDSGER TA: Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005; 52: 2425-32.
26. TORMEY VJ, BUNN CC, DENTON CP, BLACK CM: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001; 40: 1157-62.
27. AGGARWAL R, LUCAS M, FERTIG N, ODDIS C V, MEDSGER TA: Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60: 1112-8.
28. FERTIG N, DOMSIC RT, RODRIGUEZ-REYNA T et al.: Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61: 958-65.
29. MITRI GM, LUCAS M, FERTIG N, STEEN VD, MEDSGER TA: A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48: 203-9.
30. DENTON CP, ONG VH: Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 2013: 9: 451-64.
31. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
32. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
33. STRATTON RJ, WILSON H, BLACK CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40: 84-8.
34. NIHTYANOVA SI, BROUGH GM, BLACK CM, DENTON CP: Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 2007; 46: 442-5.
35. MENDOZA FA, NAGLE SJ, LEE JB, JIMENEZ SA: A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39: 1241-7.
36. DERK CT, GRACE E, SHENIN M, NAIK M, SCHULZ S, XIONG W: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1595-9.
37. POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
38. Van den HOOGEN FH, BOERBOOMS AM, SWAAK AJ, RASKER JJ, van LIER HJ, van de PUTTE LB: Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-72.
39. BURT RK, SHAH SJ, DILL K et al.: Auto-logous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506.
40. Van LAAR JM, FARGE D, SONT JK et al.: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis. 2012: 64: 4167-74.
41. BOURNIA V-K, EVANGELOU K, SFIKAKIS PP: Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum 2013; 42: 377-90.
42. SPIERA RF, GORDON JK, MERSTEN JN et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
43. DISTLER O, DISTLER J, VARGA J et al.: A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis. Arthritis Rheum 2010; 62: S233.
44. KHANNA D, SAGGAR R, MAYES MD et al.: A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-6.
45. PREY S, EZZEDINE K, DOUSSAU A et al.: Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012; 167: 1138-44.
46. POPE J, McBAIN D, PETRLICH L et al.: Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011; 63: 3547-51.
47. DAOUSSIS D, LIOSSIS S-NC, TSAMANDAS AC et al.: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49: 271-80.
48. DAOUSSIS D, LIOSSIS S-NC, TSAMANDAS AC et al.: Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30: S17-22.
49. SMITH V, Van PRAET JT, VANDOOREN B et al.: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69: 193-7.
50. SMITH V, PIETTE Y, van PRAET JT et al.: Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013; 40: 52-7.
51. MASLYANSKIY AL, LAPIN SV, KOLESOVA EP et al.: Effects of rituximab therapy on elastic properties of vascular wall in patients with progressive systemic sclerosis. Clin Exp Rheumatol 2014. [Epub ahead of print]
52. KEIR GJ, MAHER TM, HANSELL DM et al.: Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40: 641-8.
53. LEVY Y, SHERER Y, LANGEVITZ P et al.: Original article skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report 2000: 207-11.
54. NACCI F, RIGHI A, CONFORTI ML et al.: Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007; 66: 977-9.
55. LEVY Y, AMITAL H, LANGEVITZ P et al.: Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004; 50: 1005-7.
56. TAKEHARA K, IHN H, SATO S: A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013; 31: S151-6.
57. QUILLINAN NP, McINTOSH D, VERNES J, HAQ S, DENTON CP: Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis 2014; 73: 56-61.
58. POSTLETHWAITE AE, FURST DE, WONG WK et al.: Oral tolerance induction to type I collagen significantly reduces the skin score in patients with diffuse systemic sclerosis with late-phase disease. Results of a NIAMS/NIAID multicentre phase II placebo controlled double blind clinical trial [abstract]. ACR Annual Meeting 2005. Presentation number L28.
59. STEEN VD, LANZ JK, CONTE C, OWENS GR, MEDSGER TA: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-6.
60. PAI BS, SRINIVAS CR, SABITHA L, SHENOI SD, BALACHANDRAN CN, ACHARYA S: Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int J Dermatol 1995; 34: 726-8.
61. TAKEHARA K: Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 2004; 22: S87-9.
62. SHARADA B, KUMAR A, KAKKER R et al.: Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int 1994; 14: 91-4.
63. STEEN VD, MEDSGER TA: Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-9.
64. DeMARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-9.
65. NASH RA, MCSWEENEY PA, CROFFORD LJ et al.: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study 2007; 110: 1388-96.
66. IUDICI M, van der GOES MC, VALENTINI G, BIJLSMA JWJ: Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. Clin Exp Rheumatol 2013; 31: 157-65.
67. HERRICK AL, LUNT M, WHIDBY N et al.: Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010; 37: 116-24.
68. ROBERTSON LP, MARSHALL RW, HICKLING P: Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003; 62: 267-9.
69. MAYES MD, O'DONNELL D, ROTHFIELD NF, CSUKA ME: Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004; 50: 553-7.
70. THOMPSON AE, POPE JE: Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005; 44: 145-50.
71. COLEIRO B, MARSHALL SE, DENTON CP et al.: Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 1038-43.
72. DZIADZIO M, DENTON CP, SMITH R et al.: Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42: 2646-55.
73. MADDISON P: Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology (Oxford) 2002; 41: 965-71.
74. KORN JH, MAYES M, MATUCCI-CERINIC M et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93.
75. MATUCCI-CERINIC M, DENTON CP, FURST DE et al.: Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-8.
76. HERRICK AL, van den HOOGEN F, GABRIELLI A et al.: Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011; 63: 775-82.
77. HUISSTEDE BM, HOOGVLIET P, PAULIS WD et al.: Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil 2011; 92: 1166-80.
78. CHUNG L, SHAPIRO L, FIORENTINO D et al.: MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009; 60: 870-7.
79. FRECH TM, KHANNA D, MARANIAN P, FRECH EJ, SAWITZKE AD, MURTAUGH MA: Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. Clin Exp Rheumatol 2011: 29: S22-5.
80. GOH NSL, DESAI SR, VEERARAGHAVAN S et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
81. LOTA HK, WELLS AU: The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother 2013; 14: 79-89.
82. DEMEDTS M, BEHR J, BUHL R et al.: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42.
83. GALIÈ N, HOEPER MM, HUMBERT M et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-63.
84. BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease 2000; 132: 435-43.
85. CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
86. RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
87. DENTON CP, HUMBERT M, RUBIN L, BLACK CM: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-40.
88. GALIÈ N, OLSCHEWSKI H, OUDIZ RJ et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-9.
89. GALIÈ N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.
90. GALIÈ N, BRUNDAGE BH, GHOFRANI HA et al.: Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-903.
91. GHOFRANI H-A, GALIÈ N, GRIMMINGER F et al.: Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-40.
92. HOEPER MM, BARST RJ, BOURGE RC et al.: Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-38.
93. DENTON CP, SWENY P, ABDULLA A, BLACK CM: Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994; 33: 90-2.
94. STEEN VD, COSTANTINO JP, SHAPIRO AP, MEDSGER TA: Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-7.
95. PENN H, HOWIE AJ, KINGDON EJ et al.: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-94.
96. MEDSGER TA: Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 255-73.
97. MEDSGER TA, BOMBARDIERI S, CZIRJAK L, SCORZA R, DELLA ROSSA A, BENCIVELLI W: Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21: S42-6.
98. Della ROSSA A, VALENTINI G, BOMBARDIERI S et al.: European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001; 60: 585-91.
99. VALENTINI G, Della ROSSA A, BOMBARDIERI S et al.: European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
100. VALENTINI G, BENCIVELLI W, BOMBARDIERI S et al.: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62: 901-3.
101. MINIER T, NAGY Z, BÁLINT Z et al.: Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford) 2010; 49: 1133-45.
102. MEDSGER TA, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
103. STEEN VD, MEDSGER TA: The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91.
104. SEREDNICKA K, SMYTH AE, BLACK CM, DENTON CP: Using a self-reported functional score to assess disease progression in systemic sclerosis. Rheumatology (Oxford) 2007; 46: 1107-10.
105. SMYTH AE, MacGREGOR AJ, MUKERJEE D, BROUGH GM, BLACK CM, DENTON CP: A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford) 2003; 42: 732-8.
106. KHANNA D, HAYS RD, PARK GS et al.: Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007; 57: 1280-6.
107. KHANNA D, HAYS RD, MARANIAN P et al.: Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-63.
108. MOUTHON L, RANNOU F, BÉREZNÉ A et al.: Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis 2007; 66: 1651-5.
109. LING Y, JOHNSON MK, KIELY DG et al.: Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790-6.
110. MERKEL PA, HERLYN K, MARTIN RW et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
111. KHANNA D, DISTLER O, AVOUAC J et al.: Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36: 2356-61.
112. NIHTYANOVA SI, SCHREIBER BE, ONG VH et al.: Prediction of pulmonary complications and long term survival in systemic sclerosis. Arthritis Rheumatol 2014 [Epub ahead of print].
113. KOMÓCSI A, VOROBCSUK A, FALUDI R et al.: The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012; 51: 1027-36.
114. NIHTYANOVA SI, TANG EC, COGHLAN JG, WELLS AU, BLACK CM, DENTON CP: Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109-15.